SPOTLIGHT: Nymox shares hit by panel rejection

Shares of Nymox Pharmaceuticals took a beating after the company announced that an FDA panel had rejected its kit for detecting Alzheimer's. By a 5-2 vote the panel asked for more data on verification and clarification of test results. CEO Paul Averback said in a statement that he was anticipating working with the FDA on gaining more data. Report

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.